Individuals Stopping Slimming Injections Gain Back Weight at a Quadrupled Rate Than Dieters

New research indicates that people who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who halt traditional lifestyle plans.

Published data in a leading health publication demonstrates that while overweight people can lose about a fifth of their body weight while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.

"People using these drugs must be aware of the potential of fast rebound weight gain when the medication concludes," cautioned expert Dr. Susan Jebb.

Such speed of recovery means a reversion to starting mass within about 18 months.

Comparing Approaches

The study, which reviewed 37 of trials involving thousands of patients, contrasted the effects of the injectable medications with older methods.

Scientists point out that individuals who lose weight through diet and exercise generally have a more gradual creep back—approximately 100 grams monthly—once they finish.

Explaining the Quick Regain

Experts propose the mode of action of the drugs accounts for the heightened weight return.

These medications copy a natural hormone called glucagon-like peptide-1, which helps regulate appetite.

"Artificially providing GLP-1 levels far above than normal may cause the body to produce less of its own natural GLP-1, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.

"Stopping of this hormone supplement results in appetite is no longer kept in check, making excessive eating far more likely."

An Ongoing Condition?

The NHS suggest the jabs for people with weight-linked medical conditions, alongside recommended lifestyle changes.

Many experts contend that, given the high risk of weight regain, the treatment is often life-long.

This opinion is echoed by pharmaceutical companies, who note that the results "emphasize the long-term character of excess weight," comparing it to managing diseases like high blood pressure.

Patient Accounts

People who have discontinued the jabs report a powerful return of appetite.

"I experienced a trigger flipping and you become starving," described a patient.

The struggle is exacerbated if patients have not developed permanent dietary or behavioural changes during treatment.

Significant Use

Survey data indicate that millions of people in the UK have tried these injections in the last 12 months, with interest continuing to grow.

• Use is greater among females than men.
• The 40s and 50s demographic shows the greatest level of interest.
• Many obtain the drugs through private prescriptions rather than the NHS.

In conclusion, experts stress that while the jabs are potent tools for shedding pounds, they are not a standalone cure and long-term success likely depends on combined behavioural changes.